Logo

FIDIA IN
JOINT CARE

At Fidia Farmaceutici, we are dedicated to improve the lived of individuals suffering from musculoskeletal conditions. With over 35 years of experience on intra-articular Hyaluronic Acid (IAHA) research and development, our focus is on developing innovative treatments that address the root causes of joint pain and dysfunction.

Understanding Joint Conditions

Joint conditions, such as osteoarthritis (OA) and tendinopathies, affect millions of people worldwide. These conditions are often caused by inflammation, immune system issues, or gradual deterioration of the musculoskeletal system. Common symptoms include pain, swelling, stiffness, and reduced mobility.

At Fidia Farmaceutici, innovation is at the heart of everything we do.
Our research and development team works tirelessly to create advanced treatments that address the unique needs of our patients. We are committed to providing safe, effective, and accessible solutions for joint care patient.

FIDIA IN JOINT CARE

These milestones reflect Fidia’s dedication to advancing joint care through innovative hyaluronic acid–based treatments and expanding its presence in the global market.

Our Approach

At Fidia Farmaceutici, we are dedicated to improving the lives of individuals suffering from joint-related conditions. Our approach to joint care is founded on innovation, research, and a commitment to patient well-being.

Patient Centric Approach

At Fidia Farmaceutici, our commitment to patient well-being is at the core of our joint care approach. We believe that placing the patient at the center of our efforts leads to better outcomes and improved quality of life. Here’s how we achieve this:
Hymovis® is a hydrogel based on HYADD®4 (hexadecylamide derivative of hyaluronic acid) for intra-articular injection, which allows the recovery of viscoelasticity even after repeated mechanical stress thanks to the patented MO.RE. Technology (mobile reticulum) . Hymovis® slows the progression of joint damage, improves and protects cartilage by maintaining its lubrication function and its role as a shock absorber. Hymovis® is characterized by a long residence time within the joint. Hymovis® is indicated for the treatment of pain in osteoarthritis, for the conservative treatment of meniscal knee injury, and for the improvement of joint mobility by increasing the viscosity of synovial fluid.
Hymovis® is a hydrogel based on HYADD®4 (hexadecylamide derivative of hyaluronic acid) for intra-articular injection, which allows the recovery of viscoelasticity even after repeated mechanical stress thanks to the patented MO.RE. Technology (mobile reticulum) . Hymovis® slows the progression of joint damage, improves and protects cartilage by maintaining its lubrication function and its role as a shock absorber. Hymovis® is characterized by a long residence time within the joint. Hymovis® is indicated for the treatment of pain in osteoarthritis, for the conservative treatment of meniscal knee injury, and for the improvement of joint mobility by increasing the viscosity of synovial fluid.

You are about to leave fidiajointcare.com

All information you are about to see is related to a specific selected market, including the products’ portfolio, and therefore comply to different local regulations.

Proceed